brenipatide

Brenipatide, Lilly code LY3537031, is a modified 39 amino acid peptide that activates both GIP and GLP-1 receptors. The registry has 11 records indexed under Brenipatide and 5 earlier LY3537031-only registrations. None of the 16 has posted results.

tier C · weight loss · 16 records all without posted results

verdict

Brenipatide is an investigational subcutaneous dual GIP and GLP-1 receptor agonist being studied in people. The registered program is large, but effect and safety remain unknown because no record has posted results.

why C-tier

C-tier reflects a defined molecule and a large human program without posted outcomes. Registry phase is not a result. The grade should move only when brenipatide-specific efficacy and safety data become public.

the core tension

The molecule and intended receptors are known. The clinical outcomes are not. Sixteen code-linked studies show where Lilly is testing brenipatide, while hasResults=false on every record blocks claims about weight, craving, mood, safety, or any other effect.

what it is

WHO defines brenipatide as a modified 39 amino acid peptide and a dual agonist at the GIP and GLP-1 receptors. ClinicalTrials.gov records use Brenipatide and Lilly code LY3537031 for subcutaneous study drug administration.

what it does

The WHO record establishes intended receptor pharmacology. It does not establish a clinical effect. The 16 code-linked registrations cover obesity-related, psychiatric, substance-use, respiratory, and gastrointestinal populations, but every record still lists no posted results.

origin

Eli Lilly and Company is the sponsor on the code-linked ClinicalTrials.gov records. Five earlier records are indexed only under LY3537031. Eleven later records are also indexed under the Brenipatide INN.

does it work

Unknown. ClinicalTrials.gov lists 16 exact code-linked records with planned or actual enrollment totaling 6,743 people. All 16 have hasResults set to false. Three completed phase 1 records show that studies finished, not that brenipatide works or has a general safety profile.

key facts

• molecular formula: C228H354N46O72
• amino acids: 39 amino acids, modified
• type: dual GIP and GLP-1 receptor agonist peptide
• 16 exact LY3537031 code-linked registrations
• 11 + 5 Brenipatide-indexed plus earlier code-only records
• 6 / 7 / 3 phase 1 / phase 2 / phase 3 records
• 0 registry records with posted results

frequently asked questions

What is brenipatide?

Brenipatide is Lilly's LY3537031, a modified 39 amino acid peptide that activates both GIP and GLP-1 receptors. Human studies use subcutaneous administration. It remains investigational.

What does the human evidence show?

ClinicalTrials.gov has 16 exact code-linked registrations: 11 indexed under Brenipatide and 5 earlier LY3537031-only records. The program includes 6 phase 1, 7 phase 2, and 3 phase 3 records. All 16 list no posted results, so efficacy and a general safety profile remain unknown.

Is there a public brenipatide protocol?

No approved label or public routine-use protocol was found. The registry establishes study routes and protocols, not a dose, titration, contraindication list, or reconstitution guide for public use.

related peptides

• retatrutide: lilly's triple agonist, the metabolic flagship
• tirzepatide: lilly's approved GIP/GLP-1 benchmark
• survodutide: another investigational incretin still in phase 3

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.